Literature DB >> 16733107

Staging of esophageal carcinoma in a low-volume EUS center compared with reported results from high-volume centers.

Evelyn P M van Vliet1, Marinus J C Eijkemans, Jan-Werner Poley, Ewout W Steyerberg, Ernst J Kuipers, Peter D Siersema.   

Abstract

BACKGROUND: It is well known that a learning curve exists for performing EUS.
OBJECTIVE: To determine whether the number of EUS investigations performed in a center affects the results of esophageal cancer staging.
DESIGN: We compared EUS in the evaluation of T stage and the presence of regional and celiac lymph nodes in a low-volume center where <50 EUS/endoscopist/y were performed with reported results from 7 high-volume EUS centers.
SETTING: A reference center for esophageal cancer (>90 cases/y) but a low-volume center for EUS when it comes to individual endoscopists. PATIENTS: From 1994 to 2003, 244 patients underwent EUS, without specific measures to pass a stenotic tumor or FNA and with postoperative TNM stage as the criterion standard in the low-volume EUS center. In the high-volume centers, 670 EUS investigations for esophageal cancer were performed, if needed, with dilation, and with postoperative TNM stage and/or FNA as the criterion standard.
INTERVENTIONS: Retrospective analysis. MAIN OUTCOME MEASUREMENTS: Sensitivity and specificity of EUS for esophageal cancer staging.
RESULTS: In the low-volume center, results of EUS for T3 staging in patients in whom passage of the EUS probe was possible were almost comparable for sensitivity (85% vs 88%-94%) but were lower for specificity (57% vs 75%-90%), whereas both sensitivity (58% vs 75%-90%) and specificity (87% vs 94%-97%) for T1 or T2 stages were lower than those reported in the high-volume centers. In the low-volume center, sensitivities of EUS for regional (45% vs 63%-89%) and celiac (19% vs 72%-83%) lymph nodes were lower, whereas specificities (75% vs 63%-82% and 99% vs 85%-100%, respectively) were comparable with those from high-volume centers. Results in the low-volume EUS center were worse if the EUS probe could not pass the stricture, which occurred in almost 30% of patients. LIMITATIONS: Both FNA and dilation before EUS for stenotic tumors were not performed in the low-volume EUS center.
CONCLUSIONS: The results of EUS performed in a low-volume EUS center compared unfavorably with those reported from high-volume EUS centers. The results of this study suggest that preoperative staging by EUS should be performed by experienced and dedicated EUS endoscopists to optimize staging of esophageal cancer.

Entities:  

Mesh:

Year:  2006        PMID: 16733107     DOI: 10.1016/j.gie.2006.01.053

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  10 in total

Review 1.  Service provision and training for endoscopic ultrasound in the UK.

Authors:  J Meenan; K Harris; K Oppong; C McKay; I Penman; N Carroll; S Norton
Journal:  Frontline Gastroenterol       Date:  2011-04-08

Review 2.  Accuracy of endoscopic ultrasound in esophageal cancer staging.

Authors:  Timothy Krill; Michelle Baliss; Russel Roark; Michael Sydor; Ronald Samuel; Jenine Zaibaq; Praveen Guturu; Sreeram Parupudi
Journal:  J Thorac Dis       Date:  2019-08       Impact factor: 2.895

3.  Endoscopic ultrasound with conventional probe and miniprobe in preoperative staging of esophageal cancer.

Authors:  Rudolf Mennigen; Dirk Tuebergen; Gabriele Koehler; Cristina Sauerland; Norbert Senninger; Matthias Bruewer
Journal:  J Gastrointest Surg       Date:  2007-09-06       Impact factor: 3.452

4.  Performance of EUS-FNA for mediastinal lymphadenopathy: impact on patient management and costs in low-volume EUS centers.

Authors:  Meike M C Hirdes; Matthijs P Schwartz; Kristien M A J Tytgat; Noël J Schlösser; Daisy M D S Sie-Go; Menno A Brink; Bas Oldenburg; Peter D Siersema; Frank P Vleggaar
Journal:  Surg Endosc       Date:  2010-02-23       Impact factor: 4.584

5.  In vivo characterization of pancreatic and lymph node tissue by using EUS spectrum analysis: a validation study.

Authors:  Ronald E Kumon; Michael J Pollack; Ashley L Faulx; Kayode Olowe; Farees T Farooq; Victor K Chen; Yun Zhou; Richard C K Wong; Gerard A Isenberg; Michael V Sivak; Amitabh Chak; Cheri X Deng
Journal:  Gastrointest Endosc       Date:  2009-11-17       Impact factor: 9.427

Review 6.  Imaging strategies in the management of oesophageal cancer: what's the role of MRI?

Authors:  Peter S N van Rossum; Richard van Hillegersberg; Frederiek M Lever; Irene M Lips; Astrid L H M W van Lier; Gert J Meijer; Maarten S van Leeuwen; Marco van Vulpen; Jelle P Ruurda
Journal:  Eur Radiol       Date:  2013-02-13       Impact factor: 5.315

7.  The emerging field of radiomics in esophageal cancer: current evidence and future potential.

Authors:  Peter S N van Rossum; Cai Xu; David V Fried; Lucas Goense; Laurence E Court; Steven H Lin
Journal:  Transl Cancer Res       Date:  2016-08       Impact factor: 1.241

8.  Staging investigations for oesophageal cancer: a meta-analysis.

Authors:  E P M van Vliet; M H Heijenbrok-Kal; M G M Hunink; E J Kuipers; P D Siersema
Journal:  Br J Cancer       Date:  2008-01-22       Impact factor: 7.640

Review 9.  The Role of Magnetic Resonance Imaging in the Management of Esophageal Cancer.

Authors:  Anna Pellat; Anthony Dohan; Philippe Soyer; Julie Veziant; Romain Coriat; Maximilien Barret
Journal:  Cancers (Basel)       Date:  2022-02-23       Impact factor: 6.639

10.  Detection of distant metastases in patients with oesophageal or gastric cardia cancer: a diagnostic decision analysis.

Authors:  E P M van Vliet; E W Steyerberg; M J C Eijkemans; E J Kuipers; P D Siersema
Journal:  Br J Cancer       Date:  2007-09-11       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.